Codexis

Codexis Earns Milestone Payment from GlaxoSmithKline

Retrieved on: 
Mercoledì, Luglio 7, 2021
Companies, Codexis, Life sciences, Biotechnology companies, GlaxoSmithKline, GSK

REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK).

Key Points: 
  • REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK).
  • The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter.
  • Codexis is proud that our CodeEvolver platform continues to offer robust value to GSK, said John Nicols, President and CEO of Codexis.
  • Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product

Retrieved on: 
Giovedì, Giugno 17, 2021
Codexis, Guidance, Earnings guidance, Companies, Academic disciplines, Technology

The majority of this order was not included in Codexis prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million.

Key Points: 
  • The majority of this order was not included in Codexis prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million.
  • Codexis is also increasing its 2021 guidance for product revenue to a range of $45 million to $48 million, up from previous guidance of $36 million to $39 million.
  • In addition, the Company is raising 2021 guidance for product gross margin to a range of 60% to 64%, up from previous guidance of 54% to 58%.
  • Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver platform to discover and develop novel, high performance enzymes and novel biotherapeutics.

Codexis to Participate in Upcoming Virtual Healthcare Conferences

Retrieved on: 
Martedì, Maggio 25, 2021
Codexis, Biomolecules, Catalysis, Metabolism, Process chemicals, Chemistry, Enzyme, Physical sciences, NASDAQ, Natural sciences

REDWOOD CITY, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, todayannounced that management will participate in three upcoming virtual investment conferences.

Key Points: 
  • REDWOOD CITY, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, todayannounced that management will participate in three upcoming virtual investment conferences.
  • The Jefferies Virtual Healthcare Conference June 1, 2021 at 4:30 p.m.
  • ET a live webcast of the fireside chat presentation will be available in the Investor Relations section of the Companys website, http://ir.codexis.com .
  • Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver platform to discover and develop novel, high performance enzymes and novel biotherapeutics.

Codexis to Participate in Upcoming Virtual Healthcare Conferences

Retrieved on: 
Lunedì, Maggio 17, 2021
Articles, Biology, Life sciences, Codexis, Synthetic biology, Virtual event, NASDAQ, Calif

b'REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.\nThe UBS Global Healthcare Virtual Conference \xe2\x80\x93 May 24, 2021 at 11:00 a.m.

Key Points: 
  • b'REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.\nThe UBS Global Healthcare Virtual Conference \xe2\x80\x93 May 24, 2021 at 11:00 a.m.
  • ET, corporate presentation; a live webcast of the conference presentation will be available in the Investor Relations section of the Company\xe2\x80\x99s website, http://ir.codexis.com .
  • Replays of the webcast will be archived for 30 days following the event.\nThe SynBioBeta Synthetic Biology Biopharma Conference \xe2\x80\x93 May 26, 2021 at 11:10 a.m.
  • Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.

Codexis Reports First Quarter 2021 Financial Results

Retrieved on: 
Giovedì, Maggio 6, 2021
Codexis, Intel X99

b'REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.\n\xe2\x80\x9cCodexis\xe2\x80\x99 growth drivers are continuing to accelerate, and we began 2021 with strong momentum, especially in higher margin product sales within our Performance Enzymes segment,\xe2\x80\x9d said John Nicols, Codexis President and CEO.

Key Points: 
  • b'REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.\n\xe2\x80\x9cCodexis\xe2\x80\x99 growth drivers are continuing to accelerate, and we began 2021 with strong momentum, especially in higher margin product sales within our Performance Enzymes segment,\xe2\x80\x9d said John Nicols, Codexis President and CEO.
  • The first quarter of 2021 was Codexis\xe2\x80\x99 strongest ever for new Life Science Tools customer-partnered R&D programs.\nIn the novel Biotherapeutics market, Codexis\xe2\x80\x99 pipeline includes 12 programs.
  • Product revenues for the first quarter 2021 were $10.2 million compared to $5.1 million in first quarter 2020; the increase was the result of higher sales of branded pharmaceutical products.
  • The increase was driven by increased sales of higher margin products.\nR&D expenses for the first quarter 2021 were $11.6 million compared to $11.0 million in the first quarter 2020.

Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical Officer

Retrieved on: 
Martedì, Aprile 20, 2021
Amgen, Codexis, Biotechnology companies, Companies, Life sciences

b'SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ --Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Celia Lin, MD, as Chief Medical Officer.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ --Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Celia Lin, MD, as Chief Medical Officer.
  • Dr. Lin brings extensive clinical and industry experience in orphan diseases and multiple therapeutic areas, including nephrology and inflammation.
  • Previously, she was a medical director in clinical development and medical affairs at Amgen where she led teams and activities related to the approval and commercialization of two osteoporosis therapies.\nDr.
  • Dr. Thomas joined Vera Therapeutics from Codexis, Inc., where he served as Associate VP, Technical Operations, overseeing preclinical development for biotherapeutic products and management of external contract manufacturing partnerships.

Codexis to Present at Upcoming Virtual Healthcare Conferences

Retrieved on: 
Giovedì, Febbraio 18, 2021
Codexis, SVB Leerink, Companies, NASDAQ, Finance, Economy of the United States

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.
  • The SVB Leerink 10th Annual Global Healthcare Conference February 26, 2021 at 1:40 p.m.
  • ET
    The Cowen 41st Annual Health Care Conference March 4, 2021 at 12:50 p.m.
  • Codexis proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.

Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25

Retrieved on: 
Giovedì, Febbraio 11, 2021
Codexis, Forward-looking statement, Financial risk, NASDAQ, Economy of the United States, Finance, Companies

REDWOOD CITY, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market.
  • Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Companys financial results and provide a business update.
  • Participants may access the live webcast on the Codexis Investor Relations website , where it will be archived for 90 days.
  • Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.

Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth

Retrieved on: 
Martedì, Febbraio 9, 2021
Codexis

This facility will provide space for additional research and development laboratories and related office space.

Key Points: 
  • This facility will provide space for additional research and development laboratories and related office space.
  • We are investing in this expansion of our operations to enable further growth in our discovery and R&D capacity, said John Nicols, President and CEO of Codexis.
  • We anticipate these trends will continue accelerating, with new partnerships in these verticals, as well as self-funded clinical development programs.
  • The brand-new facility is expected to be ready for occupancy in the fourth quarter of 2021 and to accommodate approximately 90 employees.

Codexis Appoints Dr. Esther Martinborough to its Board of Directors

Retrieved on: 
Mercoledì, Febbraio 3, 2021
Codexis, Martinborough

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.
  • As we grow and invest in Codexis Biotherapeutics business, we are extremely fortunate to have Dr. Martinborough join our board of directors.
  • Her guidance will be an invaluable resource to Codexis, and we are very pleased to welcome Dr. Martinborough to the Codexis board, said Bernard Kelley, Chairman of Codexis.
  • Im delighted to join the Codexis board of directors and look forward to supporting the Companys many opportunities to leverage its platform to advance new products and therapeutics, said Dr. Martinborough.